migraine. Migraine, unspecified
Conditions
Interventions
Intervention group: 30 mg/day Coenzyme Q10 with 250 mg/day L-carnitine at the same time for 8- weeks
control group: placebo tablets for 8 weeks.
Treatment - Drugs
Intervention group: 30 mg/day Coenzyme Q10 with 250 mg/day L-carnitine at the same time for 8- weeks
control group: placebo tablets for 8 weeks
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: patients with migraine (with or without aura) both sex nonpregnant nonlactative nonsmokers non-alcoholic willing to participate in the study
Exclusion criteria
Exclusion criteria: contain history of chronic diseases chronic tension-type headache or secondary headaches medication or supplements use following a diet program during the past 6 month following exercise program during the past 6 month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Migraine symptoms ( severity , frequency and average duration of migraine attacks). Timepoint: week 0 and week 8. Method of measurement: Questionaire.;Serum Lactate. Timepoint: week 0 and week 8. Method of measurement: Laboratory analysis (blood test). | — |
Secondary
| Measure | Time frame |
|---|---|
| Migraine Disability Assessment. Timepoint: week 0 and week 8. Method of measurement: Questinaire.;Depression. Timepoint: week 0 and week 8. Method of measurement: Questinaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParisa Hashemi
Isfahan University of Medical Sciences
Outcome results
None listed